| Field | Specification |
|---|---|
| Target | |
| Alternative names | Vascular endothelial growth factor receptor 2; VEGFR-2; 2.7.10.1; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD309; KDR; FLK1, VEGFR2; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human VEGF Receptor 2 recombinant protein (Position: A20-L242). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets vascular endothelial growth factor receptor 2 (gene KDR) in human samples and is validated for flow cytometry, IHC, ICC/IF and Western blot. The predicted molecular weight is 151.5 kDa, and the supplier reports an observed band at about 180–250 kDa.
VEGFR2 (KDR, also called FLK1) is a receptor tyrosine kinase on endothelial cells that binds VEGF-A as well as processed VEGF-C and VEGF-D. Ligand binding triggers receptor dimerization and autophosphorylation, activating PLCγ, PI3K/AKT and MAPK signaling that drives endothelial proliferation, migration, survival and vascular permeability. VEGFR2 is the main mediator of VEGF-driven angiogenesis and a major target of anti-angiogenic cancer drugs.
| Target | Vascular endothelial growth factor receptor 2 (gene KDR; UniProt P35968, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 151.5 kDa |
| Observed MW | 180–250 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 0.5–1 µg/mL |
| Flow cytometry | Not specified by the supplier |
Samples with a confirmed band (WB): human placenta tissue, human PC-3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue, human lung cancer tissue, human placenta tissue, human mammary cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Recombinant human VEGF Receptor 2 fragment (Ala20–Leu242), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places vascular endothelial growth factor receptor 2 in the cell junction, endoplasmic reticulum and cell membrane. Tissue expression noted by UniProt (human): Detected in cornea (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xuechun Wang et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell Reports Medicine. 10.1016/j.xcrm.2026.102885
Chen Ke et al. (2023) Inhibition of infantile hemangioma growth and promotion of apoptosis via VEGF/PI3K/Akt axis by 755-nm long-pulse alexandrite laser. Biomedical Journal. 10.1016/j.bj.2023.100675
Lujie Ye et al. (2024) Dysregulated VEGF/VEGFR-2 Signaling and Plexogenic Lesions in the Embryonic Lungs of Chickens Predisposed to Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 10.3390/ijms25084489
Mengya Zhong et al. (2020) TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer. International Journal of Biological Sciences. 10.7150/ijbs.37906
Zhou Dexiang et al. (2011) A study of the Distribution and Density of the VEGFR-2 Receptor on Glioma Microvascular Endothelial Cell Membranes. Cellular and Molecular Neurobiology. 10.1007/s10571-011-9665-6
Yalin Zhu et al. (2014) Effects of propranolol and isoproterenol on infantile hemangioma endothelial cells in vitro. Experimental and Therapeutic Medicine. 10.3892/etm.2014.1780
